Markets:

Overview

News

Currencies

International

Treasuries

United Therapeutics Corporation - Common Stock (NQ:UTHR)

494.13 -9.56 (-1.90%)

Streaming Delayed Price Updated: 1:23 PM EST, Jan 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about United Therapeutics Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

Unveiling 6 Analyst Insights On United Therapeutics ↗

July 08, 2024

Via Benzinga

3 Undervalued Stocks on Track to Double (or More) by 2028 ↗

July 08, 2024

The stock market is on the brink of a multi-year bull market. Consider these undervalued growth stocks to buy that can double or more by 2028.

Via InvestorPlace

Members of Congress Buy and Sell Stocks. These ETFs Let You Invest Like Democrats or Republicans. ↗

July 02, 2024

Whether you'd like to invest like Nancy Pelosi or Ted Cruz, you can. But maybe you shouldn't.

Via The Motley Fool

Topics ETFs

7 Undervalued Biotech Stocks to Buy for Big-Time Returns ↗

July 01, 2024

The broader healthcare sector enjoys a powerfully relevant narrative. Undervalued biotech stocks makes the case even more attractive.

Via InvestorPlace

Chart Of The Day: United Therapeutics - Drugs For Chronic Illnesses ↗

June 28, 2024

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening...

Via Talk Markets

Deep Dive Into United Therapeutics Stock: Analyst Perspectives (5 Ratings) ↗

June 12, 2024

Via Benzinga

Expert Ratings For United Therapeutics ↗

May 21, 2024

Via Benzinga

The Latest Analyst Ratings For United Therapeutics ↗

May 02, 2024

Via Benzinga

UroGen Pharma Stock Earns 91 RS Rating ↗

June 27, 2024

UroGen Pharma stock had its Relative Strength (RS) Rating upgraded to 91 Thursday, up from 87 a day earlier.

Via Investor's Business Daily

United Therapeutics Corporation Announces Election of Jan Malcolm to its Board of Directors

June 27, 2024

From United Therapeutics Corporation

Via Business Wire

When you look at NASDAQ:UTHR, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. ↗

June 26, 2024

UNITED THERAPEUTICS CORP (NASDAQ:UTHR) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.

Via Chartmill

Arcellx Stock Earns Relative Strength Rating Upgrade ↗

June 21, 2024

One key metric to look for in a stock is an 80-plus Relative Strength Rating. Arcellx stock cleared that benchmark Friday, jumping to 83.

Via Investor's Business Daily

The 3 Best Medical Device Stocks to Buy in June 2024 ↗

June 20, 2024

Medical devices are at the forefront of the digitalization of medicine. making these the three best medical device stocks to buy.

Via InvestorPlace

Intra-Cellular Therapies Stock Scores RS Rating Upgrade To 87 ↗

June 20, 2024

Intra-Cellular Therapies sees its Relative Strength Rating enter the 80-plus level.

Via Investor's Business Daily

10 Health Care Stocks Whale Activity In Today's Session ↗

June 19, 2024

Via Benzinga

Neurocrine Biosciences Stock Tops Milestone Amid New Drug Plans ↗

June 14, 2024

Neurocrine Biosciences has long been known for its blockbuster drug Ingrezza. It's diversifying, developing multiple drugs in related areas.

Via Investor's Business Daily

Madrigal Pharmaceuticals Stock Earns RS Rating Upgrade ↗

June 12, 2024

On Wednesday, Madrigal Pharmaceuticals stock earned an upgrade to its Relative Strength (RS) Rating, from 74 to 90.

Via Investor's Business Daily

Krystal Biotech Stock Sees RS Rating Jump To 91 ↗

June 11, 2024

On Tuesday, Krystal Biotech stock cleared a key technical benchmark, seeing its Relative Strength Rating jump to 91 from 88.

Via Investor's Business Daily

10 Health Care Stocks With Whale Alerts In Today's Session ↗

June 11, 2024

Via Benzinga

Halozyme Therapeutics Scores RS Rating Jump To 91 ↗

June 07, 2024

On Friday, Halozyme Therapeutics stock earned an upgrade to its Relative Strength (RS) Rating, from 80 to 91.

Via Investor's Business Daily

For those who appreciate value investing, NASDAQ:UTHR is a compelling option with its solid fundamentals. ↗

June 05, 2024

Investors should take notice ofUNITED THERAPEUTICS CORP (NASDAQ:UTHR)—it offers a great deal for the fundamentals it presents.

Via Chartmill

United Therapeutics Corporation to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

June 05, 2024

From United Therapeutics Corporation

Via Business Wire

The 3 Most Undervalued Healthcare Stocks to Buy in June 2024 ↗

June 04, 2024

Seeking discounts in relevant places makes sense and there are few arenas more compelling than undervalued healthcare stocks.

Via InvestorPlace

Liquidia Stock Surges After Winning Patent Battle Vs. United Therapeutics ↗

June 03, 2024

Liquidia stock retook its 50-day line Monday on a U.S. judge's ruling on a patent dispute with fellow biotech company United Therapeutics.

Via Investor's Business Daily

Topics Intellectual Property

7 Biotech Stocks That Could Breathe New Life Into Your Portfolio ↗

May 20, 2024

Thanks to the underlying pertinence, these established biotech stocks to buy offer confidence to investors facing tricky market conditions.

Via InvestorPlace

Halozyme Therapeutics Stock Earns IBD Stock Rating Upgrade, Hitting 80-Plus RS Rating ↗

May 16, 2024

On Thursday, biotech Halozyme Therapeutics stock had its Relative Strength (RS) Rating upgraded to 84, up from 80 a day earlier.

Via Investor's Business Daily

NASDAQ:UTHR is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗

May 15, 2024

UNITED THERAPEUTICS CORP (NASDAQ:UTHR), an undervalued stock with good fundamentals.

Via Chartmill

Catalyst Pharmaceuticals Stock Clears Technical Benchmark With 83 RS Rating ↗

May 14, 2024

On Tuesday, Catalyst Pharmaceuticals stock hit a key technical milestone, with its Relative Strength Rating climbing to 83 from 79.

Via Investor's Business Daily

3 Biotech Stocks to Double Your Money in the Next 24 Months ↗

May 06, 2024

The biotech sector offers significant potential for growth. These 3 biotech stocks to double your money are noteworthy candidates.

Via InvestorPlace

Lung Disease-Focused United Therapeutics Says It Is A Compelling Investment Opportunity ↗

May 01, 2024

United Therapeutics impresses with record-breaking Q1 results. Revenue soars 34% Y/Y to $677.7 million, EPS jumps to $6.17. Tyvaso leads the charge with a 56% revenue surge.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.